Prague, Czechia

Petr Bilek

This inventor holds 1 USPTO granted patent and 2 EPO patents. Top assignee: Spofa, Spojene Podniky Pro Zdravotnickou Vyrobu. Active years: 1987.


% Patents Active = 100.0

 

Average Co-Inventor Count = 13.0

ph-index = 1

Forward Citations = 24(Granted Patents)


Company Filing History:


Years Active: 1987

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Petr Bilek: Innovator in Veterinary Medicine

Introduction

Petr Bilek is a notable inventor based in Prague, Czech Republic. He has made significant contributions to the field of veterinary medicine, particularly through his innovative methods for treating endometritis in mammalian females. His work has the potential to improve the health and well-being of farm animals, such as cows.

Latest Patents

Petr Bilek holds a patent for a method for the treatment of endometritis in mammalian females. This invention involves the administration of 1-(8-alpha-ergolinyl)-3,3-diethylurea derivatives, which are designed to address chronic and/or acute puerperal inflammations. The compound is particularly advantageous in veterinary medicine, providing a therapeutic solution for farm animals.

Career Highlights

Throughout his career, Petr Bilek has worked with several prominent companies, including Spofa, Spojene Podniky Pro Zdravotnickou Vyrobu, and Valeo Systèmes Thermiques. His experience in these organizations has contributed to his expertise in developing effective treatments for veterinary applications.

Collaborations

Petr Bilek has collaborated with notable colleagues such as Antonin Cerny and Jiri Krepelka. These partnerships have likely enhanced his research and development efforts in the field of veterinary medicine.

Conclusion

Petr Bilek's innovative approach to treating endometritis in mammals showcases his dedication to improving animal health. His contributions to veterinary medicine are significant and reflect his commitment to advancing the field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…